Market Closed -
Nasdaq
01:30:00 27/04/2024 am IST
|
5-day change
|
1st Jan Change
|
4.8
USD
|
+1.91%
|
|
-5.70%
|
-31.62%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
732.2
|
657.3
|
1,055
|
316.1
|
446.5
|
308.7
|
-
|
-
|
Enterprise Value (EV)
1 |
732.2
|
657.3
|
1,055
|
316.1
|
446.5
|
308.7
|
308.7
|
308.7
|
P/E ratio
|
-12.1
x
|
-9.83
x
|
-13.2
x
|
-2.27
x
|
-4.71
x
|
-2.72
x
|
3.61
x
|
7.11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
55.1
x
|
42.2
x
|
28
x
|
19.9
x
|
31.9
x
|
5.54
x
|
1.13
x
|
0.75
x
|
EV / Revenue
|
55.1
x
|
42.2
x
|
28
x
|
19.9
x
|
31.9
x
|
5.54
x
|
1.13
x
|
0.75
x
|
EV / EBITDA
|
-
|
-11.3
x
|
-16.2
x
|
-2.94
x
|
-3.62
x
|
-3.27
x
|
5.47
x
|
-
|
EV / FCF
|
6,61,72,702
x
|
-77,42,368
x
|
-1,85,51,192
x
|
-26,77,187
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
36,572
|
43,412
|
44,449
|
48,477
|
63,597
|
64,307
|
-
|
-
|
Reference price
2 |
20.02
|
15.14
|
23.74
|
6.520
|
7.020
|
4.800
|
4.800
|
4.800
|
Announcement Date
|
11/03/20
|
11/03/21
|
10/03/22
|
14/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
13.29
|
15.56
|
37.7
|
15.92
|
14.02
|
55.77
|
273
|
409
|
EBITDA
1 |
-
|
-58.38
|
-65.32
|
-107.6
|
-123.3
|
-94.37
|
56.47
|
-
|
EBIT
1 |
-58.27
|
-62.55
|
-73.19
|
-116.4
|
-137.1
|
-124.4
|
134.6
|
52.36
|
Operating Margin
|
-438.37%
|
-401.94%
|
-194.14%
|
-730.87%
|
-977.82%
|
-222.99%
|
49.33%
|
12.8%
|
Earnings before Tax (EBT)
1 |
-54.75
|
-57.99
|
-79.56
|
-129.6
|
-84.03
|
-126.2
|
132.9
|
48.06
|
Net income
1 |
-54.75
|
-57.99
|
-79.56
|
-129.6
|
-84.03
|
-126.2
|
132.9
|
48.06
|
Net margin
|
-411.87%
|
-372.63%
|
-211.03%
|
-814.16%
|
-599.46%
|
-226.25%
|
48.68%
|
11.75%
|
EPS
2 |
-1.650
|
-1.540
|
-1.800
|
-2.870
|
-1.490
|
-1.762
|
1.330
|
0.6750
|
Free Cash Flow
|
11.06
|
-84.89
|
-56.88
|
-118.1
|
-
|
-
|
-
|
-
|
FCF margin
|
83.24%
|
-545.47%
|
-150.87%
|
-741.59%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
11/03/21
|
10/03/22
|
14/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
6.947
|
21.04
|
5.633
|
10.76
|
4.816
|
-5.288
|
3.334
|
3.54
|
5.103
|
2.04
|
9.688
|
9.688
|
9.688
|
10.62
|
9.946
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-22.55
|
-8.124
|
-28.73
|
-23.76
|
-22.81
|
-41.06
|
-31.76
|
-28.78
|
-32.76
|
-43.75
|
-31.36
|
-32.54
|
-34.21
|
-34.45
|
17.05
|
Operating Margin
|
-324.63%
|
-38.61%
|
-510.1%
|
-220.82%
|
-473.59%
|
776.38%
|
-952.61%
|
-813.14%
|
-642.01%
|
-2,144.8%
|
-323.74%
|
-335.87%
|
-353.16%
|
-324.24%
|
171.44%
|
Earnings before Tax (EBT)
1 |
-25.94
|
-9.912
|
-31.04
|
-33.97
|
-37.28
|
-27.31
|
-30.36
|
-29.58
|
-44.3
|
20.22
|
-31.94
|
-33.61
|
-35.29
|
-36.02
|
16.48
|
Net income
1 |
-25.94
|
-9.912
|
-31.04
|
-33.97
|
-37.28
|
-27.31
|
-30.36
|
-29.58
|
-44.3
|
20.22
|
-31.94
|
-33.61
|
-35.29
|
-36.02
|
16.48
|
Net margin
|
-373.47%
|
-47.1%
|
-551.13%
|
-315.76%
|
-774.17%
|
516.51%
|
-910.74%
|
-835.62%
|
-868.06%
|
990.93%
|
-329.67%
|
-346.96%
|
-364.25%
|
-339.05%
|
165.66%
|
EPS
2 |
-0.5900
|
-0.2200
|
-0.7000
|
-0.7600
|
-0.8300
|
-0.5800
|
-0.6200
|
-0.5300
|
-0.7400
|
0.4200
|
-0.5050
|
-0.4950
|
-0.5250
|
-0.5150
|
0.2400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
10/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
14/03/23
|
11/05/23
|
10/08/23
|
14/11/23
|
14/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
11.1
|
-84.9
|
-56.9
|
-118
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-27%
|
-37.5%
|
-85.5%
|
-65.7%
|
-100%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-1.700
|
-0.2400
|
-1.620
|
-1.870
|
0.0100
|
1.820
|
-
|
Capex
|
8.98
|
20.9
|
46.4
|
45
|
-
|
-
|
-
|
-
|
Capex / Sales
|
67.56%
|
134.44%
|
122.94%
|
282.43%
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
11/03/21
|
10/03/22
|
14/03/23
|
14/03/24
|
-
|
-
|
-
|
Average target price
21.6
USD Spread / Average Target +350.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -31.62% | 309M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|